Novel drugs to treat hemophilia
作者： Leonard A Valentino , Yousef Ismael , Michele Grygotis
DOI: 10.1517/14728214.2010.506871
关键词:
摘要: Importance of the field: Hemophilia management requires replacement deficient clotting factor. Inhibitor development complicates treatment, and implementation adherence to prophylaxis, considered standard care for severe hemophilia, is hampered by high cost need frequent intravenous infusions. New, less expensive therapies are needed reduce morbidities, enhance convenience improve outcomes. Areas covered in this review: We conducted a search Medline database from 1990 2010 English language articles pertaining hemophilia drug therapy. More than 4000 citations were obtained examined topic relevance. Additionally, proceedings American Society Hematology, International on Thrombosis Hemostasis, World Federation Hemophilia, National Foundation European Association Haemophilia Allied Disorders ClinicalTrials.gov website reviewed relevant publications information. What t...
informahealthcare.com参考文章(132)
Frits Rosendaal, Louis Aledort, Jeanne Lusher, Chantal Rothschild, Jørgen Ingerslev, Gilbert White, Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thrombosis and Haemostasis. ,vol. 85, pp. 560- 560 ,(2001) , 10.1055/S-0037-1615621
B.M. Ewenstein, C. Takemoto, I. Warrier, J. Lusher, P. Saidi, J. Eisele, L. J. Ettinger, D. DiMichele, Nephrotic Syndrome as a Complication of Immune Tolerance in Hemophilia B Blood. ,vol. 89, pp. 1115- 1116 ,(1997) , 10.1182/BLOOD.V89.3.1115
C Negrier, J Goudemand, Y Sultan, M Bertrand, C Rothschild, P Lauroua, , Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thrombosis and Haemostasis. ,vol. 77, pp. 1113- 1119 ,(1997) , 10.1055/S-0038-1656122
Alan B. Colowick, Rhonda L. Bohn, Jerry Avorn, Bruce M. Ewenstein, Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood. ,vol. 96, pp. 1698- 1702 ,(2000) , 10.1182/BLOOD.V96.5.1698
Johannes Walter, Katherine A. High, Gene therapy for the hemophilias. Advances in Veterinary Medicine. ,vol. 40, pp. 119- 134 ,(1997) , 10.1016/S0065-3519(97)80006-7
Gilbert C White, Aime Beebe, Brenda Nielsen, Recombinant factor IX. Thrombosis and Haemostasis. ,vol. 78, pp. 261- 265 ,(1997) , 10.1055/S-0038-1657536
H.H. Brackmann, T. Wallny, Immune Tolerance: High‐Dose Regimen Blackwell Science Ltd. pp. 45- 48 ,(2008) , 10.1002/9780470757260.CH7
E Berntorp, P Mannucci, V Boulyjenkov, D Brettler, I Peak, P Jones, M Chandy, C Lee, K Rickard, J Lusher, Modern treatment of haemophilia Bulletin of The World Health Organization. ,vol. 73, pp. 691- 701 ,(1995)
A Shapiro, M Manco-Johnson, G rd White, EM Gordon, GL Bray, E Scheibel, S Courter, ED Gomperts, M Lee, R Gruppo, A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood. ,vol. 83, pp. 2428- 2435 ,(1994) , 10.1182/BLOOD.V83.9.2428.BLOODJOURNAL8392428
H. SAITO, I. MARUYAMA, S. SHIMAZAKI, Y. YAMAMOTO, N. AIKAWA, R. OHNO, A. HIRAYAMA, T. MATSUDA, H. ASAKURA, M. NAKASHIMA, N. AOKI, Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial Journal of Thrombosis and Haemostasis. ,vol. 5, pp. 31- 41 ,(2007) , 10.1111/J.1538-7836.2006.02267.X